#ICYMI: @BlueRockTx unveiled new details into a phase 3 registrational trial testing its stem cell therapy bemdaneprocel in patients with Parkinson's. 

Expected to begin 1H 2025, it is the first and only such trial for a stem cell therapy in PD.
#ICYMI